# Vivmark Residential: financial statements, quarterly

VMRK · NYSE · CIK 906107 · [Real estate](/sectors/real-estate.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/vmrk.md) · [Financials](/companies/vmrk/financials.md) · [Filings](/companies/vmrk/filings.md) · [Insiders](/companies/vmrk/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/vmrk/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [252](/filings/0000950170-23-058214.md) | [393 d](/filings/0000950170-24-015907.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.3](/filings/0000950170-24-120716.md) | [0.3 d](/filings/0001193125-26-051433.md) | [0.3](/filings/0000950170-25-061082.md) | [0.3](/filings/0000950170-25-104090.md) | [0.3](/filings/0001193125-25-258599.md) | [0.3 d](/filings/0001193125-26-051433.md) | [0.4](/filings/0001193125-26-197417.md) | [0.4](/filings/0001193125-26-326170.md) | [0.4](/filings/0001193125-25-258599.md) | [0.4 d](/filings/0001193125-26-051433.md) | [0.4](/filings/0001193125-26-197417.md) | [0.4](/filings/0001193125-26-326170.md) |
| Net income | $m | [173](/filings/0000950170-24-120716.md) | [312 d](/filings/0001193125-26-051433.md) | [296](/filings/0000950170-25-061082.md) | [177](/filings/0000950170-25-104090.md) | [143](/filings/0001193125-25-258599.md) | [419 d](/filings/0001193125-26-051433.md) | [257](/filings/0001193125-26-197417.md) | [192](/filings/0001193125-26-326170.md) | [289](/filings/0001193125-25-258599.md) | [382 d](/filings/0001193125-26-051433.md) | [90.1](/filings/0001193125-26-197417.md) | [114](/filings/0001193125-26-326170.md) |
| Diluted EPS | $ per share | [0.45](/filings/0000950170-24-120716.md) | not reported | [0.77](/filings/0000950170-25-061082.md) | [0.47](/filings/0000950170-25-104090.md) | [0.38](/filings/0001193125-25-258599.md) | not reported | [0.67](/filings/0001193125-26-197417.md) | [0.50](/filings/0001193125-26-326170.md) | [0.76](/filings/0001193125-25-258599.md) | not reported | [0.24](/filings/0001193125-26-197417.md) | [0.30](/filings/0001193125-26-326170.md) |
| Basic EPS | $ per share | [0.45](/filings/0000950170-24-120716.md) | not reported | [0.78](/filings/0000950170-25-061082.md) | [0.47](/filings/0000950170-25-104090.md) | [0.38](/filings/0001193125-25-258599.md) | not reported | [0.68](/filings/0001193125-26-197417.md) | [0.51](/filings/0001193125-26-326170.md) | [0.76](/filings/0001193125-25-258599.md) | not reported | [0.24](/filings/0001193125-26-197417.md) | [0.30](/filings/0001193125-26-326170.md) |

- Revenue: not reported
- Gross profit: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [0.0](/filings/0000950170-24-120716.md) | [0.1](/filings/0001193125-26-051433.md) | [0.0](/filings/0000950170-25-061082.md) | [0.0](/filings/0000950170-25-104090.md) | [0.0](/filings/0001193125-25-258599.md) | [0.1](/filings/0001193125-26-051433.md) | [0.0](/filings/0001193125-26-197417.md) | [0.0](/filings/0001193125-26-326170.md) | [0.1](/filings/0001193125-25-258599.md) | [0.1](/filings/0001193125-26-326170.md) | [0.0](/filings/0001193125-26-197417.md) | [0.0](/filings/0001193125-26-326170.md) |
| Total assets | $bn | [20.1](/filings/0000950170-23-058214.md) | [20.0](/filings/0000950170-25-019894.md) | [19.9](/filings/0000950170-24-052144.md) | [19.8](/filings/0000950170-24-089300.md) | [20.9](/filings/0000950170-24-120716.md) | [20.8](/filings/0001193125-26-051433.md) | [20.6](/filings/0000950170-25-061082.md) | [21.0](/filings/0000950170-25-104090.md) | [21.1](/filings/0001193125-25-258599.md) | [20.7](/filings/0001193125-26-326170.md) | [20.5](/filings/0001193125-26-197417.md) | [20.3](/filings/0001193125-26-326170.md) |
| Total liabilities | $bn | [8.6](/filings/0000950170-23-058214.md) | [8.5](/filings/0000950170-25-019894.md) | [8.3](/filings/0000950170-24-052144.md) | [8.3](/filings/0000950170-24-089300.md) | [9.5](/filings/0000950170-24-120716.md) | [9.2](/filings/0001193125-26-051433.md) | [9.0](/filings/0000950170-25-061082.md) | [9.5](/filings/0000950170-25-104090.md) | [9.6](/filings/0001193125-25-258599.md) | [9.3](/filings/0001193125-26-326170.md) | [9.5](/filings/0001193125-26-197417.md) | [9.4](/filings/0001193125-26-326170.md) |
| Long-term debt | $bn | not reported | [7.5](/filings/0000950170-24-015907.md) | not reported | not reported | not reported | [8.2](/filings/0000950170-25-019894.md) | not reported | not reported | not reported | [8.2](/filings/0001193125-26-051433.md) | not reported | not reported |
| Short-term borrowings | $bn | [1.0](/filings/0000950170-23-058214.md) | [0.4](/filings/0000950170-24-015907.md) | [1.0](/filings/0000950170-24-052144.md) | [1.0](/filings/0000950170-24-089300.md) | [1.0](/filings/0000950170-24-120716.md) | [0.5](/filings/0000950170-25-019894.md) | [1.5](/filings/0000950170-25-061082.md) | [1.5](/filings/0000950170-25-104090.md) | [1.5](/filings/0001193125-25-258599.md) | [0.6](/filings/0001193125-26-051433.md) | [1.5](/filings/0001193125-26-197417.md) | [1.5](/filings/0001193125-26-326170.md) |
| Shareholders' equity | $bn | [11.1](/filings/0000950170-23-058214.md) | [11.1](/filings/0000950170-25-019894.md) | [11.1](/filings/0000950170-24-052144.md) | [11.0](/filings/0000950170-24-089300.md) | [10.9](/filings/0000950170-24-120716.md) | [11.0](/filings/0001193125-26-051433.md) | [11.0](/filings/0000950170-25-061082.md) | [11.0](/filings/0000950170-25-104090.md) | [11.1](/filings/0001193125-25-258599.md) | [11.0](/filings/0001193125-26-326170.md) | [10.7](/filings/0001193125-26-197417.md) | [10.5](/filings/0001193125-26-326170.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Short-term borrowings: us-gaap:CommercialPaper
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [443 d](/filings/0000950170-24-120716.md) | [344 d](/filings/0001193125-26-051433.md) | [421](/filings/0000950170-25-061082.md) | [397 d](/filings/0000950170-25-104090.md) | [401 d](/filings/0001193125-25-258599.md) | [354 d](/filings/0001193125-26-051433.md) | [426](/filings/0001193125-26-197417.md) | [360 d](/filings/0001193125-26-326170.md) | [477 d](/filings/0001193125-25-258599.md) | [387 d](/filings/0001193125-26-051433.md) | [401](/filings/0001193125-26-197417.md) | [302 d](/filings/0001193125-26-326170.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Dividends paid | $m | [251 d](/filings/0000950170-24-120716.md) | [252 d](/filings/0001193125-26-051433.md) | [251](/filings/0000950170-25-061082.md) | [256 d](/filings/0000950170-25-104090.md) | [256 d](/filings/0001193125-25-258599.md) | [256 d](/filings/0001193125-26-051433.md) | [256](/filings/0001193125-26-197417.md) | [263 d](/filings/0001193125-26-326170.md) | [263 d](/filings/0001193125-25-258599.md) | [264 d](/filings/0001193125-26-051433.md) | [262](/filings/0001193125-26-197417.md) | [263 d](/filings/0001193125-26-326170.md) |
| Share repurchases | $m | not reported | not reported | [38.5](/filings/0000950170-25-061082.md) | [0.0 d](/filings/0000950170-25-104090.md) | [0.0 d](/filings/0001193125-25-258599.md) | [0.0 d](/filings/0001193125-26-051433.md) | not reported | not reported | not reported | [186 d](/filings/0001193125-26-051433.md) | [219](/filings/0001193125-26-197417.md) | [0.0 d](/filings/0001193125-26-326170.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [389](/filings/0000950170-23-058214.md) | [391](/filings/0000950170-24-052144.md) | [391](/filings/0000950170-24-089300.md) | [391](/filings/0000950170-24-120716.md) | [391](/filings/0000950170-25-061082.md) | [391](/filings/0000950170-25-104090.md) | [391](/filings/0001193125-25-258599.md) | [391](/filings/0001193125-26-197417.md) | [391](/filings/0001193125-26-326170.md) | [391](/filings/0001193125-25-258599.md) | [385](/filings/0001193125-26-197417.md) | [384](/filings/0001193125-26-326170.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 374,944,409 at 2026-07-24, from the cover of the [10-Q filed 2026-07-30](/filings/0001193125-26-326170.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:28 ET. No prices; not investment advice.